What is on the differential diagnosis for Choledocholithiasis and Ascending Cholangitis?

Key differentials include Acute cholecystitis without CBD involvement, Hepatitis (viral, alcoholic, drug-induced), Pancreatic head malignancy, Cholangiocarcinoma, Primary sclerosing cholangitis, Biliary stricture (post-surgical, ischemic), Mirizzi syndrome, Acute pancreatitis.

What are the high-yield PANCE pearls for Choledocholithiasis and Ascending Cholangitis?

Charcot triad (fever + RUQ pain + jaundice) = ascending cholangitis until proven otherwise; Reynolds pentad adds hypotension and altered mental status (severe). Urgent biliary drainage is the cornerstone of cholangitis treatment — antibiotics alone are insufficient. ERCP is therapeutic (sphincterotomy + stone extraction) and should be used selectively given pancreatitis risk; for diagnosis, use MRCP or EUS. Rectal indomethacin reduces post-ERCP pancreatitis risk in high-risk patients (Elmunzer, NEJM 2012). Same-admission cholecystectomy after CBD stone extraction reduces readmission and complications (PONCHO trial). Painless jaundice with palpable distended gallbladder (Courvoisier sign) suggests malignancy (pancreatic head cancer, cholangiocarcinoma) — NOT stones. Brown pigment stones in Asian patients suggest biliary parasitic infection (Clonorchis, Ascaris) and chronic recurrent chola

Gastrointestinal · PANCE / PANRE

Choledocholithiasis and Ascending Cholangitis

Written & clinically reviewed by Ryan Busch, PA-C · Updated July 2026 · Report an error

CBD stones cause obstructive jaundice; superimposed infection produces ascending cholangitis.

Also known as: choledocholithiasis, CBD stones, ascending cholangitis, Charcot triad, Reynolds pentad

Overview

Choledocholithiasis: gallstones in the common bile duct (CBD). Ascending cholangitis: bacterial infection of the biliary tree, typically resulting from biliary obstruction (stone, stricture, malignancy) and ascending bacterial colonization, presenting with Charcot triad (fever, jaundice, RUQ pain) or Reynolds pentad (Charcot + hypotension + altered mental status).

Epidemiology

Choledocholithiasis present in 10-20% of patients with gallstones. Cholangitis affects 1-9% of patients with CBD stones; mortality 5-10% with prompt treatment, up to 50% if untreated or with severe sepsis.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Choledocholithiasis and Ascending Cholangitis outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Cholelithiasis (primary risk factor)
Prior cholecystectomy with retained or de novo CBD stones
Asian biliary parasitic infection (Clonorchis, Ascaris) → brown pigment stones
Biliary strictures (PSC, post-surgical, malignant)
Indwelling biliary stents
Choledochal cysts
Biliary anomalies

Pathophysiology

CBD stone obstructs flow → biliary stasis and increased pressure → bacterial proliferation (E. coli, Klebsiella, Enterobacter, Enterococcus, anaerobes) → ascending infection → bacteremia and sepsis. Increased intrabiliary pressure drives translocation of bacteria into the bloodstream.

Clinical presentation

Symptoms

Choledocholithiasis: RUQ pain, jaundice, dark urine, pale stools, pruritus
Cholangitis (Charcot triad): fever, RUQ pain, jaundice
Cholangitis (Reynolds pentad): Charcot triad + hypotension + altered mental status (severe/suppurative)
Nausea, vomiting
Rigors

Signs / physical exam

Jaundice, scleral icterus
RUQ tenderness
Fever, tachycardia
Hypotension if severe (Reynolds pentad)
Altered mental status — sepsis-induced encephalopathy
Excoriations from pruritus
Hepatomegaly possible

Classic findings

Charcot triad (fever + RUQ pain + jaundice) in any patient with gallstones — assume cholangitis until proven otherwise; this is a surgical/endoscopic emergency.

Differential diagnosis

Acute cholecystitis without CBD involvement — Murphy sign, gallbladder wall thickening on US, normal CBD diameter, mildly elevated LFTs only
Hepatitis (viral, alcoholic, drug-induced) — Markedly elevated AST/ALT, viral serologies; alk phos and bili less elevated proportionally
Pancreatic head malignancy — Painless jaundice, Courvoisier sign (palpable nontender gallbladder), weight loss; mass on imaging
Cholangiocarcinoma — Painless jaundice, irregular biliary stricture on MRCP/EUS
Primary sclerosing cholangitis — Beaded biliary strictures on MRCP; IBD association; pANCA+
Biliary stricture (post-surgical, ischemic) — Prior cholecystectomy, transplant
Mirizzi syndrome — Cystic duct stone compressing CBD; MRCP/EUS
Acute pancreatitis — Pain to back, lipase >3× ULN — may coexist with biliary obstruction

Diagnostic workup

Diagnostic criteria

ASGE risk stratification for CBD stones (2019): High probability (any 1 of: CBD stone on imaging; total bilirubin >4 mg/dL WITH a dilated CBD; or clinical ascending cholangitis) → proceed to ERCP. Intermediate (CBD dilation + elevated LFTs + bilirubin 1.8-4) → MRCP or EUS. Low → cholecystectomy alone. Tokyo Guidelines TG18 for cholangitis: A) systemic inflammation (fever, leukocytosis, CRP); B) cholestasis (jaundice, abnormal LFTs); C) imaging (biliary dilation, evidence of cause). Diagnosis requires 1 from each category.

Labs

CBC — leukocytosis with left shift
BMP — assess for AKI in sepsis
LFTs — elevated direct bilirubin, alk phos, GGT (cholestatic pattern); AST/ALT also elevated
Lipase — exclude or identify concurrent pancreatitis
Coagulation studies — INR may rise (vitamin K malabsorption in prolonged cholestasis)
Blood cultures × 2 — guide antibiotic therapy
Lactate, procalcitonin if septic

Imaging

RUQ ultrasound — first-line; identifies gallstones, dilated CBD (>6 mm in patients <60, >8 mm post-cholecystectomy), but sensitivity for CBD stones only 20-50%
MRCP — non-invasive, high sensitivity (>90%) for CBD stones
EUS — most sensitive for small CBD stones; preferred when MRCP equivocal
ERCP — diagnostic AND therapeutic; reserved for high-probability or therapeutic intent (do not use diagnostically due to pancreatitis risk)
CT — alternative when malignancy suspected; less sensitive for non-calcified stones

Diagnostic algorithm

flowchart TD
  A[Suspected biliary disease<br/>RUQ pain + jaundice] --> B[Labs + RUQ US]
  B --> C{Charcot triad?<br/>Fever + RUQ pain<br/>+ jaundice}
  C -->|Yes — cholangitis| D[IV fluids + broad-spectrum<br/>antibiotics<br/>URGENT ERCP within 24h]
  C -->|No| E{CBD stone probability<br/>ASGE 2019}
  E -->|High: CBD stone seen<br/>or bili >4 + clinical cholangitis| F[ERCP with sphincterotomy<br/>+ stone extraction]
  E -->|Intermediate| G[MRCP or EUS]
  G --> H{Stone present?}
  H -->|Yes| F
  H -->|No| I[Laparoscopic cholecystectomy<br/>± intraop cholangiogram]
  E -->|Low| I
  D --> J[Cholecystectomy after recovery]
  F --> J

Choledocholithiasis and cholangitis pathway — ASGE 2019 risk stratification and Tokyo Guidelines management.

Treatment

First-line

Resuscitation: IV fluids, hemodynamic support
Broad-spectrum IV antibiotics covering Gram-negative and anaerobes — piperacillin-tazobactam, ceftriaxone + metronidazole, or carbapenem for severe sepsis/multi-drug-resistant risk
URGENT biliary drainage by ERCP with sphincterotomy and stone extraction — within 24-48 h for moderate cholangitis, within 24 h for severe cholangitis
Percutaneous transhepatic cholangiography (PTC) drainage if ERCP fails or contraindicated (post-Roux-en-Y anatomy)
Surgical decompression (open CBD exploration) — rarely required as rescue
Cholecystectomy after recovery (same admission or within 4-6 weeks) to prevent recurrence

Choledocholithiasis WITHOUT cholangitis (high probability of stones)

ERCP with sphincterotomy and stone extraction PRIOR to cholecystectomy (preferred)
Or laparoscopic cholecystectomy with intraoperative cholangiography and laparoscopic CBD exploration

Ascending cholangitis — TG18 severity

Grade I (mild): IV antibiotics + non-urgent biliary drainage within 24-48 h
Grade II (moderate): early biliary drainage (within 24 h) + antibiotics
Grade III (severe — organ dysfunction): emergent drainage + ICU-level care + antibiotics; mortality remains 10-20%

Second-line / adjunct

EUS-guided biliary drainage if ERCP fails
Mechanical lithotripsy, balloon dilation, or large-balloon sphincteroplasty for large or difficult stones
Biliary stent placement if stones cannot be extracted at first ERCP (allows decompression and drainage; second-look ERCP later)
Source control of malignant obstruction with stent (plastic or self-expanding metal)

Complications

Septic shock, multiorgan failure
Hepatic abscess
Acute pancreatitis (post-ERCP or stone-induced)
Bile peritonitis (post-procedure)
Recurrent stones
Secondary biliary cirrhosis (chronic obstruction)
Biliary stricture
Cholangiocarcinoma (chronic biliary inflammation, especially with parasitic infection — recurrent pyogenic cholangitis)

PANCE pearls

Charcot triad (fever + RUQ pain + jaundice) = ascending cholangitis until proven otherwise; Reynolds pentad adds hypotension and altered mental status (severe).
Urgent biliary drainage is the cornerstone of cholangitis treatment — antibiotics alone are insufficient.
ERCP is therapeutic (sphincterotomy + stone extraction) and should be used selectively given pancreatitis risk; for diagnosis, use MRCP or EUS.
Rectal indomethacin reduces post-ERCP pancreatitis risk in high-risk patients (Elmunzer, NEJM 2012).
Same-admission cholecystectomy after CBD stone extraction reduces readmission and complications (PONCHO trial).
Painless jaundice with palpable distended gallbladder (Courvoisier sign) suggests malignancy (pancreatic head cancer, cholangiocarcinoma) — NOT stones.
Brown pigment stones in Asian patients suggest biliary parasitic infection (Clonorchis, Ascaris) and chronic recurrent cholangitis.
Post-cholecystectomy CBD diameter is normally larger (up to 10 mm) — recalibrate sonographic thresholds.
Mirizzi syndrome: external compression of CBD by cystic duct stone — preoperative MRCP critical to avoid bile duct injury.

References

Tokyo Guidelines TG18 — Kiriyama S et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis. J Hepatobiliary Pancreat Sci 2018;25:17-30
ASGE 2019 — ASGE Standards of Practice Committee. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc 2019;89:1075-1105
PONCHO Trial — da Costa DW et al. Same-admission versus interval cholecystectomy for mild gallstone pancreatitis (PONCHO). Lancet 2015;386:1261-1268
Rectal Indomethacin — Elmunzer BJ et al. A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis. NEJM 2012;366:1414-1422

Practice Gastrointestinal questions on FirstPassPA

Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.